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The effectiveness of ibrutinib in chronic lymphocytic
leukaemia: a nationwide, population-based study in the
Netherlands
At present, in the Netherlands, the application in daily prac-
tice of ibrutinib in patients with chronic lymphocytic leukae-
mia (CLL) is, as yet, restricted to CLL patients with del(17p)
or a TP53 mutation across all treatment lines, and in particu-
lar to patient subsets with previously treated CLL (Kersting
et al., 2018).
Efficacy data derived from the RESONATE trial (Byrd
et al., 2014) — which led to the approval of ibrutinib for
the abovementioned indications — cannot always be readily
extrapolated into “real-world” effectiveness. This issue
relates to the restricted patient selection criteria in clinical
trials (Meyer, 2010). Most population-based information on
the effectiveness of ibrutinib in CLL currently derives from
compassionate-use programmes (CUPs) and series in which
patients were primarily managed in academic centres (Win-
qvist et al., 2016; Ysebaert et al., 2017; Hillmen et al.,
2018). Such series might also suffer from patient selection,
as in clinical trials. Therefore, this nationwide, population-
based study aimed to assess the effectiveness of ibrutinib
among CLL patients in a post-approval setting in the
Netherlands.
All CLL patients who initiated treatment with commer-
cially available ibrutinib between 2015 and 2016 in the
Netherlands were identified and queried via the Nationwide
Registry of Hospital Discharges (i.e. inpatient and outpatient
discharges) and the nationwide Netherlands Cancer Registry.
Details about the registries are provided in the Supporting
information.
The primary endpoint was progression-free survival (PFS).
The secondary endpoints included assessment of the applica-
tion of ibrutinib according to the Dutch guidelines by
HOVON, duration and toxicity of ibrutinib treatment, over-
all survival (OS), and event-free survival (EFS). Survival dis-
tributions were constructed using the Kaplan-Meier method
and compared using the log-rank test. Regression analyses
were performed to assess various covariates associated with
ibrutinib discontinuation and survival outcomes. Details
about the endpoints (Table SI) and statistical methods are
described in the Supporting information.
All 155 ibrutinib-treated CLL patients [median age 70 years
(range: 48–91 years), 74% males; 67% Rai stage III–IV; 68%
managed in non-university hospitals; 6% with small lympho-
cytic lymphoma] were included in the study. Patient charac-
teristics are presented in Table SII.
At a median follow-up of 142 months (range 09–319),
75 (48%) patients were still receiving ibrutinib and 45 (29%)
patients had died. Reasons for ibrutinib discontinuation and
the best response rate are described in the Supporting infor-
mation. Overall, the median time on ibrutinib was
116 months (range 01–309). Multivariable logistic regres-
sion showed that Rai stage III–IV — especially anaemia —
was the sole covariate associated with ibrutinib discontinua-
tion (Table SIII).
The median PFS (95% CI: 229, median not reached) and OS
(95% CI: median not reached) were not reached (Fig 1). One-
year PFS and OS were 73% (95% CI, 65–79%) and 77% (95%
CI, 69–83%) respectively (Fig 1). Multivariable Cox regression
analyses revealed that Rai stage III-IV (HR for PFS, 256;
95% CI: 126–519 and HR for OS, 254; 95% CI: 117–
555) (Table IA) — particularly anaemia (HR for PFS, 409;
95% CI 202–828 and HR for OS, 361; 95% CI 169–770)
(Table IB) — and the number of previous therapies per one
treatment line increase (HR for PFS, 127; 95% CI: 104–155
and HR for OS, 129; 95%CI: 104–160) were associated with
inferior PFS and OS, respectively. Besides, haepato- and/or sple-
nomegaly (HR for OS, 316; 95% CI: 112–892) was only asso-
ciated with inferior OS (Table IB).
The median EFS and one-year EFS were 182 months
(95% CI, 116, median not reached) and 58% (95% CI, 50–
66%), respectively (Fig 1). Multivariable Cox regression
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Fig 1. Survival outcomes. Abbreviations: PFS, progression-free sur-
vival; OS, overall survival; and EFS, event-free survival.
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analyses showed that anaemia — but not Rai stage III–IV or
thrombocytopenia — was the only covariate associated with
inferior EFS (Table IA, B).
Exploratory survival analyses according to (i) the line of
therapy, (ii) the presence of TP53 aberrations or (iii) anaemia,
(iv) the application of ibrutinib as per the Dutch guidelines by
HOVON, and (v) the experience of a grade 3 or 4 adverse
event (AE) are presented in the Supporting information.
Grade 3 or 4 AEs during ibrutinib treatment were noted in
73 (47%) patients and are listed in Table SIV. Of note, AEs
occurred more abundantly in patients with anaemia, as com-
pared to patients without anaemia (57% vs. 38%; P = 0021).
In our population-based study, one-year PFS and OS are
slightly inferior to the one-year PFS (84%) and OS (90%)
reported in the RESONATE trial (Byrd et al., 2014), 10-
months PFS (77%) and OS (83%) in the Swedish CUP
(Winqvist et al., 2016), and one-year PFS (74%) and OS
(84%) in the international CUP (Hillmen et al., 2018)
respectively. However, as a result of a higher discontinuation
rate in our study compared to the aforementioned studies,
one-year EFS was 58%. Several arguments can be brought
forward to discuss disparities related to these outcomes. In
the aforementioned studies, patient inclusion relies on refer-
ral practices and relatively strict inclusion and exclusion cri-
teria. Also, the median age of ibrutinib-treated CLL patients
in a US study (Mato et al., 2018) — who were managed
mainly in academic hospitals and within the setting of clini-
cal trials — was 10 years lower compared to our study pop-
ulation and the general CLL population (Kristinsson et al.,
2009; Van den Broek et al., 2012). Collectively, our study
represents general ibrutinib-treated CLL patients better. It
therefore merits acknowledgement that our study might
include a more inferior group of patients who were rather
expeditiously treated with ibrutinib following its reimburse-
ment as from late 2014 in the Netherlands. Indeed, the inclu-
sion of older, often frail patients in our study might have
contributed to early ibrutinib discontinuation. Moreover, the
discontinuation rate in our study was higher (58%) com-
pared to those reported in CUPs (range, 11–41%) and the
RESONATE trial (14%) (Byrd et al., 2014). The high discon-
tinuation rate thus highlights the need for additional and
accessible supportive-care measures in a daily practice setting
to improve the tolerability of ibrutinib, which, in turn, may
improve outcomes (Jain et al., 2015).
An interesting novel finding that emerged from our study
was that pretreatment anaemia — but not thrombocytope-
nia — was independently associated with inferior survival
outcomes and ibrutinib discontinuation. Anaemia has hith-
erto not been reported as a specific predictor of outcome in
ibrutinib-treated CLL patients. We strongly encourage that
Table I. Results of the multivariable Cox regression analysis for progression-free survival, overall survival, and event-free survival.
Section Covariate
Progression-free survival Overall survival Event-free survival
HR 95% CI P HR 95% CI P HR 95% CI P
A Age* 098 094–102 0252 099 095–103 0670 100 097–103 0877
Female sex 078 040–150 0454 090 044–180 0758 085 050–144 0538
No. of comorbidities* 116 097–139 0113 116 095–141 0136 115 099–134 0068
RAI stage
0–IIs 1 (ref) 100 (ref) 1 (ref)
III–IV 256 126–519 0009 254 117–555 0019 163 094–284 0082
Treatment as per guidelines 175 099–309 0055 173 093–321 0081 139 087–222 0168
No. of previous therapies* 127 104–155 0020 129 104–160 0019 112 094–133 0220
Prior therapy with PA and/or B 094 047–190 0870 113 052–248 0754 087 050–151 0618
B Age* 097 093–101 0160 099 095–103 0596 100 097–104 0858
Female sex 063 030–129 0204 069 032–151 0353 073 041–131 0293
No. of comorbidities* 109 088–136 0415 107 085–135 0583 109 092–130 0311
Lymphadenopathy 093 027–325 0915 099 022–447 0988 121 042–345 0720
Haepato- and/or splenomegaly 225 094–538 0068 316 112–892 0030 145 076–276 0254
Anaemia† 409 202–828 <0001 361 169–770 0001 196 115–334 0014
Thrombocytopenia‡ 090 048–170 0748 094 048–184 0855 107 064–179 0798
Treatment as per guidelines 191 104–352 0037 182 095–349 0072 148 091–240 0112
No. of previous therapies* 143 115–179 0001 146 116–184 0002 118 098–141 0080
Prior therapy with PA and/or B 075 036–156 0448 089 040–201 0782 083 047–147 0529
In section B of this Table, the Rai stage was replaced with its parameters (i.e. presence of lymphadenopathy, haepato- and/or splenomegaly, anae-
mia, and thrombocytopenia) to delineate which parameter was most critical in predicting the outcome.
Hazard ratios (HRs) denoted in bold indicate variables that are significant at the level of P < 005.
Abbreviations: B, bendamustine; CI, confidence interval; PA, purine analogue.
*Linear estimate per one unit increase.
†Anaemia defined as a haemoglobin level below 110 g/l.
‡Thrombocytopenia defined as thrombocytes below 100 9 109/l.
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the association of anaemia with outcome should be validated
in forthcoming studies.
The key strength of our study includes the use of a
nationwide registry that enabled us to identify all ibrutinib-
treated CLL patients. The omission of genetic testing in most
patients and the limited application of ibrutinib in the first-
line setting prevented meaningful subgroup analyses.
In summary, in this nationwide, population-based
study — which mainly included previously treated CLL
patients — survival outcomes with ibrutinib were lower than
reported in clinical trials and CUPs. Forthcoming popula-
tion-based studies are imperative to assess whether the out-
comes of ibrutinib-treated CLL patients will improve to the
level of clinical studies.
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